Table 1.
Participant characteristics.
| Overall | |
|---|---|
| n = 42 | |
| Demographics | |
| Age, years (mean, SD) | 45 (14.5) |
| Disease duration, years (mean, SD) | 14.5 (9.5) |
| Female | 39 (93%) |
| Race/ethnicity | |
| Non-Hispanic Black | 22 (52%) |
| Non-Hispanic White | 15 (36%) |
| Hispanic | 2 (5%) |
| Asian | 2 (5%) |
| Mixed race | 1 (2%) |
| College education | 22 (52%) |
| Medicare/Medicaid/No insurance | 20 (48%) |
| Married or living with partner | 21 (50%) |
| Number of individuals can count on for help or support | 3.5 (1.9%) |
| Serologies | |
| ANA positive | 40 (95%)a,b |
| Anti-dsDNA antibody OR Anti-Smith antibody positive | 28 (67%) |
| Low C3 and/or low C4 | 24 (57%) |
| SLE Diagnostic Criteria | |
| 1997 ACR Criteria Metc | 40 (95%) |
| SLICC Criteria Metc | 40 (95%) |
| Historical SLE Manifestations | |
| Arthritis/Joint involvement | 34 (81%) |
| Mucocutaneous | 39 (93%) |
| Renal | 15 (36%) |
| Serosal | 8 (19%) |
| Hematologic | 24 (57%) |
| Patient-Reported Historical Medication Use | |
| Hydroxychloroquine | 41 (98%) |
| Oral prednisone | 39 (93%) |
| Azathioprine | 20 (48%) |
| Methotrexate | 20 (48%) |
| Mycophenolate mofetil | 19 (45%) |
| Mycophenolic acid | 7 (17%) |
| Cyclophosphamide | 7 (17%) |
| Belimumab | 6 (14%) |
| Rituximab | 5 (12%) |
a
one participant is ANA negative but dsDNA positive
b
one participant ANA 1:40
c
n=2 participants met 1997 ACR criteria but not SLICC criteria and n=2 participants met SLICC criteria but not 1997 ACR criteria(28-29)